The estimated Net Worth of Patricia Randall is at least $682 millier dollars as of 12 March 2020. Ms. Randall owns over 15,074 units of Oxford Immunotec Global PLC stock worth over $521,691 and over the last 11 years she sold OXFD stock worth over $60,300. In addition, she makes $99,693 as Independent Director at Oxford Immunotec Global PLC.
Sign up
Ms. Randall OXFD stock SEC Form 4 insiders trading
Patricia has made over 5 trades of the Oxford Immunotec Global PLC stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 15,074 units of OXFD stock worth $1,357 on 12 March 2020.
The largest trade she's ever made was exercising 15,074 units of Oxford Immunotec Global PLC stock on 12 March 2020 worth over $1,357. On average, Patricia trades about 2,766 units every 160 days since 2014. As of 12 March 2020 she still owns at least 23,724 units of Oxford Immunotec Global PLC stock.
You can see the complete history of Ms. Randall stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Patricia Randall biography
Patricia Randall is Independent Director of the Company. Most recently, she served as our senior vice president and general counsel. Ms. Randall joined Oxford Immunotec in 2008 as general counsel and was responsible for all legal affairs of the Company through her retirement and election to the board of directors. Before joining Oxford Immunotec, from 2003 to 2008, she served as vice president, general counsel and secretary of Matritech, Inc., a biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers. She previously served as a member of senior management and general counsel of two other publicly-traded companies. Ms. Randall has practiced law for over 35 years for both public and private companies and in private practice. Until December 2017, she served as a member of the board of directors of Belmont Instrument Corporation, a private medical device company that develops, manufactures and markets critical care devices.
What is the salary of Patricia Randall?
As the Independent Director of Oxford Immunotec Global PLC, the total compensation of Patricia Randall at Oxford Immunotec Global PLC is $99,693. There are 6 executives at Oxford Immunotec Global PLC getting paid more, with Peter Wrighton-Smith having the highest compensation of $2,151,490.
How old is Patricia Randall?
Patricia Randall is 69, she's been the Independent Director of Oxford Immunotec Global PLC since 2017. There are 3 older and 7 younger executives at Oxford Immunotec Global PLC. The oldest executive at Oxford Immunotec Global PLC is Richard Sandberg, 77, who is the Independent Director.
What's Patricia Randall's mailing address?
Patricia's mailing address filed with the SEC is C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, ABINGDON, OXFORDSHIRE, X0, OX14 4RZ.
Insiders trading at Oxford Immunotec Global PLC
Over the last 11 years, insiders at Oxford Immunotec Global PLC have traded over $13,598,906 worth of Oxford Immunotec Global PLC stock and bought 47,600 units worth $549,576 . The most active insiders traders include James R Tobin, Peter Wrighton Smith et Ronald Asbury Andrews. On average, Oxford Immunotec Global PLC executives and independent directors trade stock every 36 days with the average trade being worth of $536,006. The most recent stock trade was executed by Patrick J Balthrop on 20 May 2020, trading 4,000 units of OXFD stock currently worth $49,920.
What does Oxford Immunotec Global PLC's logo look like?
Complete history of Ms. Randall stock trades at Oxford Immunotec Global PLC
Oxford Immunotec Global PLC executives and stock owners
Oxford Immunotec Global PLC executives and other stock owners filed with the SEC include:
-
Peter Wrighton-Smith,
Chief Executive Officer, Director -
Matthew McLaughlin,
Chief Financial Officer -
Richard Sandberg,
Independent Director -
Patrick Balthrop,
Independent Chairman of the Board -
Herman Rosenman,
Independent Director -
James Tobin,
Independent Director -
Patricia Randall,
Independent Director -
Andrew Walton,
Independent Director -
Mark Klausner,
Independent Director -
Ronald Andrews,
Independent Director -
Janet Kidd,
General Counsel, Company Secretary -
Herm Rosenman,
-
Richard M. Altieri,
Chief Financial Officer -
Peter Edwardson,
Chief Operations Officer -
Stephen L Spotts,
Director -
Jeff R. Schroeder,
Chief Commercial Officer -
Richard Wenstrup,
Chief Medical Officer -
Stefan C Linn,
Chief Operating Officer -
Elizabeth M Keiley,
VP & General Counsel -
Lifesciences I, L.P.Clarus ...,
-
Leaf Ventures Ii, L.P.New L...,